BioSpace News Archive

Engage Surgical, a privately held orthopedic implant company, announces FDA 510 clearance of the only cementless partial knee system available in the USA.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that the Investigational New Drug Application for MN-166 for prevention of Acute Respiratory Distress Syndrome has been accepted and is now open with the U.S. Food and Drug Administration.

Sumitomo Dainippon Pharma Oncology Is Positioned to Advance Meaningful Therapies for Patients with Cancer through Innovative Drug Discovery, Research and Development

Hallura Ltd., an Israeli aesthetic medical company developing the next generation of Hyaluronic Acid Dermal Fillers, announced that it has appointed Mr. Paul Navarre to serve as an independent director of Hallura’s Board of Directors.

Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug application for a Phase II clinical trial of Antroquinonol on COVID-19 patients in USA.

Merck, known as MSD outside the United States and Canada, will hold its second-quarter 2020 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 31.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced the appointment of Kimberly Blackwell, M.D. to its Board of Directors.

NanoMosaic was invited by the organizers of the American Association of Cancer Research to formally participate in its prestigious annual meeting with two poster presentations focused on central issues in furthering the field of oncology treatment and research

QurAlis to in-license lead excitotoxicity targeted ALS therapeutic candidates from Lilly

KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020